173 related articles for article (PubMed ID: 2809277)
21. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
Larocca AP; Leung SC; Marcus SG; Colby CB; Borden EC
J Interferon Res; 1989 Sep; 9 Suppl 1():S51-60. PubMed ID: 2809278
[TBL] [Abstract][Full Text] [Related]
22. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
Ross C; Engler CB; Sander B; Bendtzen K
J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
[TBL] [Abstract][Full Text] [Related]
23. MHC class I and II antigen expression and interferon alpha treatment of human midgut carcinoid tumors.
Makridis C; Juhlin C; Akerström G; Oberg K; Rastad J
World J Surg; 1994; 18(4):481-6; discussion 486-7. PubMed ID: 7725732
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.
Bello-Rivero I; Cervantes M; Torres Y; Ferrero J; Rodríguez E; Pérez J; García I; Díaz G; López-Saura P
J Autoimmun; 2004 Aug; 23(1):63-73. PubMed ID: 15236754
[TBL] [Abstract][Full Text] [Related]
26. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
27. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies.
Viscomi GC; Antonelli G; Bruno C; Scapol L; Malavasi F; Funaro A; Simeoni E; Pestka S; De Pisa F; Dianzani F
J Interferon Cytokine Res; 1999 Apr; 19(4):319-26. PubMed ID: 10334382
[TBL] [Abstract][Full Text] [Related]
28. Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma.
de Wit R; Bakker PJ; Danner SA; Goudsmit J; Veenhof KH
Int J STD AIDS; 1990 Jul; 1(4):256-8. PubMed ID: 2088534
[TBL] [Abstract][Full Text] [Related]
29. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.
Lallemand C; Meritet JF; Erickson R; Grossberg SE; Roullet E; Lyon-Caen O; Lebon P; Tovey MG
J Interferon Cytokine Res; 2008 Jun; 28(6):393-404. PubMed ID: 18593334
[TBL] [Abstract][Full Text] [Related]
30. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
Weck PK; Leventhal BG; Brand C; Finter NB
J Interferon Res; 1989 Sep; 9 Suppl 1():S37-43. PubMed ID: 2553830
[TBL] [Abstract][Full Text] [Related]
31. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
[TBL] [Abstract][Full Text] [Related]
32. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.
Antonelli G; Giannelli G; Currenti M; Simeoni E; Del Vecchio S; Maggi F; Pistello M; Roffi L; Pastore G; Chemello L; Dianzani F
Clin Exp Immunol; 1996 Jun; 104(3):384-7. PubMed ID: 9099919
[TBL] [Abstract][Full Text] [Related]
33. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
34. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
35. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.
Ross C; Hansen MB; Schyberg T; Berg K
Clin Exp Immunol; 1990 Oct; 82(1):57-62. PubMed ID: 2119920
[TBL] [Abstract][Full Text] [Related]
37. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.
Tefferi A; Grendahl DC
Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097
[TBL] [Abstract][Full Text] [Related]
38. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis.
Craxi A; Di Marco V; Volpes R; Palazzo U
Hepatogastroenterology; 1988 Dec; 35(6):304-5. PubMed ID: 3063647
[TBL] [Abstract][Full Text] [Related]
39. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
[TBL] [Abstract][Full Text] [Related]
40. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]